Your browser doesn't support javascript.
loading
Efficacy of initial treatment with peginterferon alpha-2a versus peginterferon alpha-2b in combination with ribavirin in naive chronic hepatitis C patients living in Daejeon and Chungcheong Province in Korea: A comparative study / 대한간학회지
The Korean Journal of Hepatology ; : 493-502, 2008.
Artigo em Coreano | WPRIM | ID: wpr-147558
ABSTRACT
BACKGROUNDS/

AIMS:

Peginterferon alpha-2a or -2b is the standard treatment regimen in chronic hepatitis C. However, there have been few comparative studies of the efficacies of these two types of peginterferon. We evaluated their efficacies in combination with ribavirin as a initial treatment for chronic hepatitis C.

METHODS:

Ninety-seven patients were treated with peginterferon alpha-2a (180 microgram/week, n=48) or peginterferon alpha-2b (1.5 microgram/kg/week, n=49) plus ribavirin (800 mg/day for 24 weeks in genotype non-1 or 1,000-1,200 mg/day for 48 weeks in genotype 1). Virologic responses including the early virologic response (EVR), end-of-treatment response (ETR), sustained virologic response (SVR), and adverse effects were analyzed retrospectively.

RESULTS:

The virologic response rates did not differ significantly between peginterferon alpha-2a and -2b 89.6% and 89.7% for EVR, 79.2% and 79.5% for ETR, 72.9% and 73.5% for SVR, respectively. Analysis of the virologic responses according to genotype also revealed no significant differences in SVR between peginterferon alpha-2a and -2b (59.3% vs. 59.7% for genotype 1 and 90.5% vs. 83.3% for genotype non-1, respectively), or in adverse effects including flu-like symptom, rash, itching, neutropenia, and thrombocytopenia.

CONCLUSIONS:

We found no significant differences in therapeutic efficacies and adverse effects between the alpha-2a and -2b types of peginterferon as the initial treatment regimen in naive chronic hepatitis C patients.
Assuntos

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Antivirais / Polietilenoglicóis / Ribavirina / Estudos Retrospectivos / Fatores de Risco / Interferon-alfa / Terapia Combinada / Hepacivirus / Hepatite C Crônica / Interferon alfa-2 Tipo de estudo: Estudo de etiologia / Estudo observacional / Fatores de risco Limite: Adulto / Humanos País/Região como assunto: Ásia Idioma: Coreano Revista: The Korean Journal of Hepatology Ano de publicação: 2008 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Antivirais / Polietilenoglicóis / Ribavirina / Estudos Retrospectivos / Fatores de Risco / Interferon-alfa / Terapia Combinada / Hepacivirus / Hepatite C Crônica / Interferon alfa-2 Tipo de estudo: Estudo de etiologia / Estudo observacional / Fatores de risco Limite: Adulto / Humanos País/Região como assunto: Ásia Idioma: Coreano Revista: The Korean Journal of Hepatology Ano de publicação: 2008 Tipo de documento: Artigo